Dae Ho Lee
About
Dae Ho Lee is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology.
According to data from OpenAlex, Dae Ho Lee has authored 91 papers receiving a total of 3.4k indexed citations (citations by other indexed papers that have themselves been cited), including 89 papers in Pulmonary and Respiratory Medicine, 66 papers in Oncology and 20 papers in Molecular Biology. Recurrent topics in Dae Ho Lee's work include Lung Cancer Treatments and Mutations (84 papers), Lung Cancer Research Studies (37 papers) and Lung Cancer Diagnosis and Treatment (27 papers). Dae Ho Lee is often cited by papers focused on Lung Cancer Treatments and Mutations (84 papers), Lung Cancer Research Studies (37 papers) and Lung Cancer Diagnosis and Treatment (27 papers). Dae Ho Lee collaborates with scholars based in South Korea, United States and Spain. Dae Ho Lee's co-authors include Myung‐Ju Ahn, Jung‐Shin Lee, Sang‐We Kim, Ji‐Youn Han, Keunchil Park, Jin Soo Lee, Sang-We Kim, Hyae Young Kim, Jin Seok Ahn and Heung Tae Kim and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.
In The Last Decade
Dae Ho Lee
89 papers receiving 3.3k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Dae Ho Lee South Korea | 27 | 2.9k | 2.4k | 940 | 587 | 200 | 91 | 3.4k | ||
| Hong‐Hong Yan China | 31 | 2.8k 1.0× | 2.5k 1.0× | 870 0.9× | 866 1.5× | 194 1.0× | 133 | 3.7k | ||
| Maximiliano Van Kooten Argentina | 9 | 3.7k 1.2× | 3.3k 1.4× | 1.1k 1.1× | 623 1.1× | 213 1.1× | 14 | 4.5k | ||
| Willemijn S.M.E. Theelen Netherlands | 16 | 3.3k 1.1× | 3.0k 1.3× | 998 1.1× | 873 1.5× | 235 1.2× | 33 | 4.4k | ||
| Riyaz Shah United Kingdom | 19 | 3.3k 1.1× | 2.8k 1.2× | 1.1k 1.2× | 708 1.2× | 146 0.7× | 48 | 3.9k | ||
| Shunichi Sugawara Japan | 36 | 3.5k 1.2× | 4.2k 1.8× | 1.1k 1.1× | 548 0.9× | 178 0.9× | 209 | 5.4k | ||
| Ichiro Takata Japan | 12 | 2.7k 0.9× | 2.3k 1.0× | 795 0.8× | 345 0.6× | 314 1.6× | 50 | 3.4k | ||
| Chong‐Rui Xu China | 27 | 3.5k 1.2× | 3.1k 1.3× | 1.0k 1.1× | 931 1.6× | 299 1.5× | 122 | 4.4k | ||
| Venice Archer United Kingdom | 9 | 3.6k 1.2× | 3.6k 1.5× | 919 1.0× | 663 1.1× | 181 0.9× | 16 | 4.6k | ||
| Yuri Rukazenkov United Kingdom | 21 | 3.7k 1.2× | 3.0k 1.3× | 1.0k 1.1× | 945 1.6× | 133 0.7× | 55 | 4.1k | ||
| Jin‐Ji Yang China | 36 | 3.9k 1.3× | 3.5k 1.5× | 1.2k 1.3× | 1.1k 1.8× | 166 0.8× | 146 | 4.9k |
Countries citing papers authored by Dae Ho Lee
Since
Specialization
Citations
This map shows the geographic impact of Dae Ho Lee's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dae Ho Lee with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dae Ho Lee more than expected).
Fields of papers citing papers by Dae Ho Lee
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Dae Ho Lee. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dae Ho Lee. The network helps show where Dae Ho Lee may publish in the future.
Co-authorship network of co-authors of Dae Ho Lee
This figure shows the co-authorship network connecting the top 25 collaborators of Dae Ho Lee. A scholar is included among the top collaborators of Dae Ho Lee based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dae Ho Lee. Dae Ho Lee is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Jeong, Hyehyun, et al.. (2024). Comparison of Clinicopathogenomic Features and Treatment Outcomes of EGFR and HER2 Exon 20 Insertion Mutations in Non–Small Cell Lung Cancer: Single-Institution Experience. Cancer Research and Treatment. 56(3). 774–784.
2.
Song, Si Yeol, Young Seob Shin, Eun Kyung Choi, et al.. (2024). Contribution of Enhanced Locoregional Control to Improved Overall Survival with Consolidative Durvalumab after Concurrent Chemoradiotherapy in Locally Advanced Non–Small Cell Lung Cancer: Insights from Real-World Data. Cancer Research and Treatment. 56(3). 785–794.
3.
Jang, Yoon Jung, Wonjun Ji, Chang‐Min Choi, et al.. (2022). Optimal Definition of Oligometastasis Showing Survival Benefits of Local Therapies during Tyrosine Kinase Inhibitor Treatment. Cancer Research and Treatment. 55(2). 468–478.
4.
Lee, Jiyun, Aaron C. Tan, Siqin Zhou, et al.. (2021). Clinical Characteristics and Outcomes in Advanced KRAS-Mutated NSCLC: A Multicenter Collaboration in Asia (ATORG-005). JTO Clinical and Research Reports. 3(1). 100261–100261.
5.
Yu, Helena A., Luis Paz‐Ares, James Chih‐Hsin Yang, et al.. (2020). Phase I Study of the Efficacy and Safety of Ramucirumab in Combination with Osimertinib in Advanced T790M-positive EGFR -mutant Non–small Cell Lung Cancer. Clinical Cancer Research. 27(4). 992–1002.
6.
Choi, Chang‐Min, Dae Ho Lee, Sang‐We Kim, et al.. (2020). Outcomes according to initial and subsequent therapies following intracranial progression in patients with EGFR-mutant lung cancer and brain metastasis. PLoS ONE. 15(4). e0231546–e0231546.
7.
Tan, Daniel Shao-Weng, Dae Ho Lee, Ross A. Soo, et al.. (2017). P3.02b-117 Phase Ib Results from a Study of Capmatinib (INC280) + EGF816 in Patients with EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC). Journal of Thoracic Oncology. 12(1). S1264–S1265.
8.
Lee, Dae Ho, Seyoung Seo, Eun Kyung Cho, et al.. (2017). P2.03a-038 Phase III Trial of Pemetrexed/Carboplatin vs Pemetrexed Only in Chemo-Naïve Elderly Non-SQCC NSCLC Patients Aged ≥ 70. Journal of Thoracic Oncology. 12(1). S911–S911.
9.
Yoon, Shinkyo, Dae Ho Lee, Deokhoon Kim, Chang‐Min Choi, & Sang‐We Kim. (2017). P2.03a-061 Randomized Phase II Trial Comparing Intercalation of Afatinib to Pemetrexed with Pemetrexed Alone after Failure of Platinum Doublet Therapy. Journal of Thoracic Oncology. 12(1). S926–S926.
10.
Kelly, Ronan J., James Chih‐Hsin Yang, Dae Ho Lee, et al.. (2017). P2.06-021 Efficacy and Safety of ASP8273 versus Erlotinib or Gefitinib as First-Line Treatment in Subjects with EGFRMut+ NSCLC. Journal of Thoracic Oncology. 12(1). S1083–S1084.
11.
Rybkin, Igor I., Egbert F. Smit, Hans‐Georg Kopp, et al.. (2016). PS01.60: Ph Ib/II, Trial of INC280 ± Erlotinib vs Platinum + Pemetrexed in Adult pts with EGFR-Mutated, cMET amplified, EGFR TKI Resistant, Advanced NSCLC. Journal of Thoracic Oncology. 11(11). S307–S308.
12.
Park, Sojung, Tai Sun Park, Chang‐Min Choi, et al.. (2015). Survival Benefit of Pemetrexed in Lung Adenocarcinoma Patients With Anaplastic Lymphoma Kinase Gene Rearrangements. Clinical Lung Cancer. 16(5). e83–e89.
13.
Choi, Yoon Ji, Dae Ho Lee, Chang‐Min Choi, et al.. (2015). Randomized phase II study of paclitaxel/carboplatin intercalated with gefitinib compared to paclitaxel/carboplatin alone for chemotherapy-naïve non-small cell lung cancer in a clinically selected population excluding patients with non-smoking adenocarcinoma or mutated EGFR. BMC Cancer. 15(1). 763–763.
14.
Kim, Go Woon, Joon Seon Song, Chang‐Min Choi, et al.. (2015). Multiple resistant factors in lung cancer with primary resistance to EGFR-TK inhibitors confer poor survival. Lung Cancer. 88(2). 139–146.
15.
Ahn, Jin Seok, Ki Hyeong Lee, Jong‐Mu Sun, et al.. (2013). A randomized, phase II study of vandetanib maintenance for advanced or metastatic non-small-cell lung cancer following first-line platinum-doublet chemotherapy. Lung Cancer. 82(3). 455–460.
16.
Lee, Dae Ho, Jung Shin Lee, Sang‐We Kim, et al.. (2013). Three-arm randomised controlled phase 2 study comparing pemetrexed and erlotinib to either pemetrexed or erlotinib alone as second-line treatment for never-smokers with non-squamous non-small cell lung cancer. European Journal of Cancer. 49(15). 3111–3121.
17.
Yoon, Dok Hyun, Sora Baek, Chang‐Min Choi, et al.. (2011). FDG-PET as a Potential Tool for Selecting Patients with Advanced Non–Small Cell Lung Cancer Who May Be Spared Maintenance Therapy after First-Line Chemotherapy. Clinical Cancer Research. 17(15). 5093–5100.
18.
Sohn, Hee-Jung, Jin‐Sook Ryu, Seung Jun Oh, et al.. (2008). [18F]Fluorothymidine Positron Emission Tomography before and 7 Days after Gefitinib Treatment Predicts Response in Patients with Advanced Adenocarcinoma of the Lung. Clinical Cancer Research. 14(22). 7423–7429.
19.
Lee, Dae Ho, Sun‐Young Kong, So Yeon Park, et al.. (2006). Epidermal growth factor receptor status in anaplastic thyroid carcinoma. Journal of Clinical Pathology. 60(8). 881–884.
20.
Lee, Dae Ho, Ji‐Youn Han, Heung Tae Kim, & Jin Soo Lee. (2006). Gefitinib is of more benefit in chemotherapy-naive patients with good performance status and adenocarcinoma histology: Retrospective analysis of 575 Korean patients. Lung Cancer. 53(3). 339–345.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Hong‐Hong Yan Breakdown of academic impact, for papers by Maximiliano Van Kooten Breakdown of academic impact, for papers by Willemijn S.M.E. Theelen Breakdown of academic impact, for papers by Riyaz Shah Breakdown of academic impact, for papers by Shunichi Sugawara Breakdown of academic impact, for papers by Ichiro Takata Breakdown of academic impact, for papers by Chong‐Rui Xu Breakdown of academic impact, for papers by Venice Archer Breakdown of academic impact, for papers by Yuri Rukazenkov Breakdown of academic impact, for papers by Jin‐Ji Yang